U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

DOI Full Paper Access

103

Citations

24

References

2020

Year

Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Sun, Heather A. Wakelee, Russell W. Madison, Alexa B. Schrock,

Clinical Cancer Research

Abstract

Taletrectinib has manageable toxicities at the MTD of 800 mg daily. Preliminary efficacy was observed in patients with crizotinib-refractory <i>ROS1<sup>+</sup></i> NSCLC.

References

	Year	Citations

Page 1